Skip to content
OpenCapital
Get started

Citius Oncology, Inc. CTOR Acquired in-process research and development

Acquired in-process research and development at other companies

Immunome logo
ImmunomeIMNM
$9.01M+44.3%

Other financials

Income statement

See full
Revenue$1.7M—
Gross profit$1.3M—
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.

The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s acquired in-process research and development?
Citius Oncology, Inc. (CTOR) reported acquired in-process research and development of $40M in Q4 2025.
How has Citius Oncology, Inc.'s acquired in-process research and development changed year-over-year?
Citius Oncology, Inc.'s acquired in-process research and development increased by 2392.9% year-over-year, from $1.6M to $40M.
What does acquired in-process research and development mean?
Represents the cash consideration paid to acquire research and development projects that have not yet reached technological feasibility. This is a critical indicator of a company's external growth strategy and investment in future product pipelines within the pharmaceutical and biotechnology sectors.